Pharmaceuticals: Global Industry Almanac, MarketLine

reportlinker.com/p01080559/Pharmaceuticals-Global-Industry-Almanac-MarketLine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Includes a five-year forecast of the industry

Americas accounts for 42.2% of the global pharmaceuticals market value.

Pfizer is the leading player in the global pharmaceuticals market, generating a 8.7% share of the market’s value.

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Table 1: Global pharmaceuticals market value: $ billion, 2007-11 37

Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2011 38

Table 3: Global pharmaceuticals market share: % share, by value, 2011 39

Table 4: Global pharmaceuticals market value forecast: $ billion, 2011-16 40

Table 6: Asia-Pacific pharmaceuticals market geography segmentation: $ billion, 2011 51

Table 263: Pfizer Inc.: key facts 450

Table 264: Pfizer Inc.: key financials ($) 451

Table 265: Pfizer Inc.: key financial ratios 451

Table 266: GlaxoSmithKline Plc: key facts 453

Table 267: GlaxoSmithKline Plc: key financials ($) 454

Table 268: GlaxoSmithKline Plc: key financials () 455

Table 269: GlaxoSmithKline Plc: key financial ratios 455

Table 270: AstraZeneca PLC: key facts 457

Table 271: AstraZeneca PLC: key financials ($) 458

Table 272: AstraZeneca PLC: key financial ratios 459

Table 273: Merck & Co., Inc.: key facts 461

Table 274: Merck & Co., Inc.: key financials ($) 462

Table 275: Merck & Co., Inc.: key financial ratios 462

Table 276: Daiichi Sankyo Co., Ltd.: key facts 464

Table 277: Daiichi Sankyo Co., Ltd.: key financials ($) 465

Table 278: Daiichi Sankyo Co., Ltd.: key financials () 465

Table 279: Daiichi Sankyo Co., Ltd.: key financial ratios 465

Table 280: Astellas Pharma Inc.: key facts 467

Table 281: Astellas Pharma Inc.: key financials ($) 468

Table 282: Astellas Pharma Inc.: key financials () 468

Table 283: Astellas Pharma Inc.: key financial ratios 468

Table 284: Novartis AG: key facts 470

Table 285: Novartis AG: key financials ($) 471

Table 286: Novartis AG: key financial ratios 471

Table 287: Ach Laboratrios Farmacuticos S.A.: key facts 473

Table 288: Medley Indstria Farmacutica Ltd: key facts 474

Table 289: Sanofi: key facts 475

Table 290: Sanofi: key financials ($) 476

Table 291: Sanofi: key financials (€) 476

Table 292: Sanofi: key financial ratios 476

Table 293: EMS Sigma Pharma: key facts 478

Table 294: Johnson & Johnson: key facts 479

Table 295: Johnson & Johnson: key financials ($) 480

Table 296: Johnson & Johnson: key financial ratios 480

Table 297: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 482

Table 298: Orifarm A/S: key facts 483

Table 299: Gedeon Richter Plc: key facts 484

Table 300: Gedeon Richter Plc: key financials ($) 485

Table 301: Gedeon Richter Plc: key financials (HUF) 485

Table 302: Gedeon Richter Plc: key financial ratios 485

Table 303: EGIS Pharmaceuticals Plc: key facts 487

Table 304: EGIS Pharmaceuticals Plc: key financials ($) 488

Table 305: EGIS Pharmaceuticals Plc: key financials (HUF) 488

Table 306: EGIS Pharmaceuticals Plc: key financial ratios 488

Table 307: Dr. Reddy’s Laboratories Limited: key facts 490

Table 308: Dr. Reddy’s Laboratories Limited: key financials ($) 491

Table 309: Dr. Reddy’s Laboratories Limited: key financials (Rs.) 491

Table 310: Dr. Reddy’s Laboratories Limited: key financial ratios 491

Table 311: Cipla Limited: key facts 493

Table 312: Cipla Limited: key financials ($) 494

Table 313: Cipla Limited: key financials (Rs.) 494

Table 314: Cipla Limited: key financial ratios 494

Table 315: Ranbaxy Laboratories Limited: key facts 496

Table 316: Ranbaxy Laboratories Limited: key financials ($) 497

Table 317: Ranbaxy Laboratories Limited: key financials (Rs.) 497

Table 318: Ranbaxy Laboratories Limited: key financial ratios 497

Table 319: Lupin Limited: key facts 499

Table 320: Lupin Limited: key financials ($) 500

Table 321: Lupin Limited: key financials (Rs.) 500

Table 322: Lupin Limited: key financial ratios 501

Table 323: Chiesi Farmaceutici S.P.A.: key facts 503

Table 324: Menarini Group, The: key facts 505

Table 325: Takeda Pharmaceutical Company Limited: key facts 506

Table 326: Takeda Pharmaceutical Company Limited: key financials ($) 507

Table 327: Takeda Pharmaceutical Company Limited: key financials () 507

Table 328: Takeda Pharmaceutical Company Limited: key financial ratios 507

Table 329: Mitsubishi Tanabe Pharma Corporation: key facts 509

Table 330: Mitsubishi Tanabe Pharma Corporation: key financials ($) 510

Table 331: Mitsubishi Tanabe Pharma Corporation: key financials () 510

Table 332: Mitsubishi Tanabe Pharma Corporation: key financial ratios 510

Table 333: Eli Lilly and Company: key facts 512

Table 334: Eli Lilly and Company: key financials ($) 513

Table 335: Eli Lilly and Company: key financial ratios 513

Table 336: Polpharma SA: key facts 515

Table 337: Pharmstandard OJSC: key facts 516

Table 338: Pharmstandard OJSC: key financials ($) 516

Table 339: Pharmstandard OJSC: key financials (RUB) 517

Table 340: Pharmstandard OJSC: key financial ratios 517

Table 341: Bayer AG: key facts 519

Table 342: Bayer AG: key financials ($) 520

Table 343: Bayer AG: key financials (€) 520

Table 344: Bayer AG: key financial ratios 521

Table 345: Aspen Pharmacare Holdings Ltd: key facts 523

Table 346: Aspen Pharmacare Holdings Ltd: key financials ($) 524

Table 347: Aspen Pharmacare Holdings Ltd: key financials (ZAR) 524

Table 348: Aspen Pharmacare Holdings Ltd: key financial ratios 524

Table 349: Daewoong Pharmaceutical Co., Ltd.: key facts 526

Table 350: Daewoong Pharmaceutical Co., Ltd.: key financials ($) 527

Table 351: Daewoong Pharmaceutical Co., Ltd.: key financials (KRW) 527

Table 352: Daewoong Pharmaceutical Co., Ltd.: key financial ratios 527

Table 353: Hanmi Holdings Co., Ltd.: key facts 529

Table 354: Hanmi Holdings Co., Ltd.: key financials ($) 530

Table 355: Hanmi Holdings Co., Ltd.: key financials (KRW) 530

Table 356: Hanmi Holdings Co., Ltd.: key financial ratios 530

Table 357: Dong-A Pharmaceutical Co., Ltd.: key facts 532

Table 358: Dong-A Pharmaceutical Co., Ltd.: key financials ($) 532

Table 359: Dong-A Pharmaceutical Co., Ltd.: key financials (KRW) 533

Table 360: Dong-A Pharmaceutical Co., Ltd.: key financial ratios 533

Table 361: Almirall S.A.: key facts 535

Table 362: Almirall S.A.: key financials ($) 535

Table 363: Almirall S.A.: key financials (€) 536

Table 364: Almirall S.A.: key financial ratios 536

SOURCE Reportlinker